The updated guidelines include 11 evidence-based recommendations for the management of atopic dermatitis in adults using phototherapy and systemic treatments.
MQ-Illustrations stock.adobe.com
The American Academy of Dermatology issued updates to the 2014 Guidelines for the Management of Atopic Dermatitis. The new guidelines were published in the Journal of the American Academy of Dermatology earlier this month.
A multidisciplinary work group developed 11 evidence-based recommendations for the management of atopic dermatitis in adults using phototherapy and systemic treatments. These include injectable biologics, oral Janus kinase (JAK) inhibitors, and older immunosuppressants, antimetabolites, and corticosteroids.
For adults with more severe atopic dermatitis or dermatitis resistant to topical treatments, the work group made strong recommendations for the use of the monoclonal antibodies Dupixent (dupilumab) and Adbry (tralokinumab). Strong recommendations were also made for the JAK inhibitors Rinvoq (upadacitinib), Cibinqo (abrocitinib), and (Olumiant) baricitinib.
All but Olumiant are FDA-approved to treat moderate to severe atopic dermatitis. Olumiant is approved for this use in Europe and is approved for rheumatoid arthritis in the United States. The drug is currently under FDA regulatory review for the potential treatment of atopic dermatitis.
Phototherapy and the antimetabolite methotrexate were conditionally recommended with proper monitoring. The immunosuppressants mycophenolate, azathioprine, and cyclosporine were also conditionally recommended with appropriate monitoring.
Lastly, the work group conditionally recommended against the use of systemic corticosteroids, adding that their use should be limited to acute, severe exacerbations. These drugs should only be used as a short-term bridge therapy to other corticosteroid-sparing treatments.
A future publication will cover guidelines for the management of pediatric atopic dermatitis the authors wrote.
Ruxolitinib Cream Proves Safe for Young Children with Atopic Dermatitis
July 22nd 2024These results were found in the TRuE-AD3 study that was presented at the Society for Pediatric Dermatology meeting earlier this month, revealing the latest round of data collected in the TRuE-AD1 and TRuE-AD2 series of studies.
Read More
Study Reveals Severe Impact of Atopic Dermatitis on Women's Quality of Life and Reproductive Health
July 15th 2024Although AD is a common condition, it’s impact on sexual function and reproductive health is not well understood. In addition, many women with AD are undertreated during pregnancy due to concerns about medication side effects.
Read More
High Sodium Intake Associated to Increased Risk of Severe Atopic Dermatitis
June 20th 2024Researchers who conducted the study, of the Universities of California in San Francisco and Berkley, suggest that cutting down on sodium could be a more cost-effective and low-risk way to help manage AD.
Read More
Highly Contagious and Hard-to-Treat Fungal Skin Infections Are Emerging, Experts Warn
June 6th 2024Experts are urging healthcare providers to be aware of these two new forms of ringworm or jock itch, known as Trichophyton mentagrophytes type VII (TMVII) and Trichophyton indotineae or T. indotineae.
Read More